Pathfinder Cell Therapy Inc
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies… Read more
Market Cap & Net Worth: Pathfinder Cell Therapy Inc (PFND)
Pathfinder Cell Therapy Inc (PINK:PFND) has a market capitalization of $66.72K ($66.72K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #51177 globally and #15860 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pathfinder Cell Therapy Inc's stock price $0.00 by its total outstanding shares 667160870 (667.16 Million).
Pathfinder Cell Therapy Inc Market Cap History: 2015 to 2025
Pathfinder Cell Therapy Inc's market capitalization history from 2015 to 2025. Data shows change from $2.07 Million to $66.72K (-37.68% CAGR).
Pathfinder Cell Therapy Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pathfinder Cell Therapy Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PFND by Market Capitalization
Companies near Pathfinder Cell Therapy Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Pathfinder Cell Therapy Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Pathfinder Cell Therapy Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Pathfinder Cell Therapy Inc's market cap moved from $2.07 Million to $ 66.72K, with a yearly change of -37.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $66.72K | 0.00% |
| 2024 | $66.72K | 0.00% |
| 2023 | $66.72K | 0.00% |
| 2021 | $66.72K | -94.74% |
| 2020 | $1.27 Million | -9.52% |
| 2019 | $1.40 Million | +75.00% |
| 2018 | $800.59K | -42.86% |
| 2017 | $1.40 Million | +162.50% |
| 2016 | $533.73K | -74.19% |
| 2015 | $2.07 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Pathfinder Cell Therapy Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $66.72K USD |
| MoneyControl | $66.72K USD |
| MarketWatch | $66.72K USD |
| marketcap.company | $66.72K USD |
| Reuters | $66.72K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.